menieres drug trial

Sound Pharmaceuticals Announces Encouraging Results in Meniere’s Disease Clinical Trial; May Go Public in 2020

SEATTLE, WASHINGTON — Biotech firm, Sound Pharmaceuticals, announced positive top-line results from a randomized, double-blind, placebo-controlled, multi-center Phase 2b study in Meniere’s Disease (MD).   Evaluating SPI-1005 vs. Placebo in Meniere’s Patients   In the study, 149 adult patients with active MD, including a hearing loss at baseline of >30 dB in one of three…

Read More
meniere's disease treatment drug trial

Sound Pharmaceuticals Says Positive Results from Phase 1b Clinical Trial in Meniere’s Disease, Starting Phase 2b

SEATTLE, WASHINGTON — Sound Pharmaceuticals, a Seattle-based biotech firm, announced this week that it has achieved positive topline results from its recently completed Phase 1b SPI-1005-151 clinical trial involving Meniere’s Disease (MD) patients. SPI-1005 is the company’s investigational new drug, which mimics and induces Glutathione Peroxidase (GPx), which has been shown to reduce the swelling or…

Read More
otonomy meniere's drug trial fails

After Disappointing Results on Phase 3 Trial of Meniere’s Drug, Otonomy Lays off Staff, Suspends Further Trials in 2017

SAN DIEGO, CALIFORNIA — Following disappointing AVERTS-1 Phase 3 trial results of OTIVIDEX in Ménière’s disease patients, Otonomy, Inc., a US-based biopharmaceutical firm, announced that the company is laying off one-third of its noncommercial staff and will not initiate any further clinical trials through the end of 2017.  With the announcement, the timing for initiation…

Read More
menieres drug auris medical otifex

Auris Medical Acquires Meniere’s Drug, AM-125, from Otifex Therapeutics for Further Development

ZUG, SWITZERLAND — Biopharmaceutical company Auris Medical Holdings announced today that it has completed the acquisition of assets related to intranasal betahistine from Otifex Therapeutics Ltd. The assets acquired by Auris Medical, including preclinical and clinical data, as well as intellectual property rights, have been fully transferred to Auris Medical according to the announcement. Together the assets form the…

Read More
sound pharmaceuticals

Sound Pharmaceuticals Hires Two New Executives to Speed Development of Meniere’s Drug

SEATTLE, WASHINGTON — Sound Pharmaceuticals, a Seattle-based biotech firm, announced this week that it has hired two senior executives. Paul Hoskins, appointed to the position of Senior Director of Clinical Operations and G. Michael Wall, appointed to the position of Senior Director of Pharmaceutical Development. The new executives join the company with substantial backgrounds in the pharmaceutical industry. Sound Pharmaceuticals hopes that…

Read More
tinnitus drug pharma hearing loss

FDA Fast Tracks Tinnitus Drug; Meniere’s Drug Completes Year-Long Safety Trial

ZUG, SWITZERLAND — Biopharmaceutical company Auris Medical Holdings announced late last month that the US Food and Drug Administration (FDA) granted Fast Track designation to its investigational drug, KeyzilenTM (AM-101).  Keyzilen is esketamine gel for intratympanic injection, intended for acute peripheral tinnitus following cochlear injury or otitis media in adults.  The Fast Track designation by the FDA of an…

Read More